Skip to main content

Table 4 Summary of 24-hour urine glucose (mmol) on day 2 by treatment

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

  Met BID RE BID Met + RE BID
N = 13 N = 13 N = 13
Mean (SD) 13.6 (13.4) 528 (130) 458 (98)
Median 10.9 497 485
Min, Max 1.1, 43.9 384, 796 242, 573